(2023)
A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES.
24,
21
(2023)
Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach.
RADIATION ONCOLOGY.
18,
1
(2023)
Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer.
CANCERS.
15,
19
(2023)
Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
CANCERS.
15,
13
(2023)
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
BREAST CANCER.
30,
3
(2023)
<i>TP53</i> mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
CANCER MEDICINE.
12,
11
(2023)
Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer.
FRONTIERS IN ONCOLOGY.
13,
-
(2022)
Efficacy of a tailored moisturizer for reducing chemotherapy-induced skin dryness in breast cancer patients: A randomized controlled clinical trial.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY.
87,
4
(2022)
Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.
FRONTIERS IN ONCOLOGY.
12,
(2022)
Correlation between work productivity loss and EORTC QLQ-C30 and-BR23 domains from the MONALEESA-7 trial of premenopausal women with HR+/HER2-advanced breast cancer.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY.
14,
(2021)
Real-world data from a refractory triple-negative breast cancer cohort selected using a clinical data warehouse approach.
CANCERS.
13,
22
(2021)
Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?.
FRONTIERS IN ONCOLOGY.
11,
(2021)
Elevated level of nerve growth factor (Ngf) in serum-derived exosomes predicts poor survival in patients with breast cancer undergoing neoadjuvant chemotherapy.
CANCERS.
13,
21
(2021)
Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype.
CLINICAL BREAST CANCER.
21,
4
(2021)
Prediction of pathologic complete response to neoadjuvant chemotherapy using machine learning models in patients with breast cancer.
BREAST CANCER RESEARCH AND TREATMENT.
189,
3
(2021)
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
BREAST CANCER RESEARCH AND TREATMENT.
188,
1
(2021)
The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial.
DISEASES OF THE ESOPHAGUS.
35,
1
(2021)
Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry.
FRONTIERS IN ONCOLOGY.
11,
(2021)
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up.
JOURNAL OF CLINICAL ONCOLOGY.
39,
13
(2021)
The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study.
FRONTIERS IN ONCOLOGY.
11,
1
단행본
(2003)
호지킨병.
일조각.
단독
학술회의논문
(2019)
Genome-wide association study predict prognosis of hormone receptor positive metastatic breast cancer in premenopausal women with endocrine therapy.
2019 SABCS.
미국
(2019)
Deep Learning Based Breast Cancer(BC) Recurrence Prediction Model Using Adjuvant BC Cohort in Tertiary Cancer Center Registry.
7th FACO International Conference.
중국
(2019)
Prediction of neoadjuvant chemotherapy response and long term survival outcome in early and locally advanced breast cancer patients.
7th FACO International Conference.
중국
(2017)
Identification of ESR1 mutation in breast cancers using targeted ultra-deep sequencing data analysis.
SABCS.
미국
(2017)
EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation.
SABCS.
미국
(2017)
The DORA trial: A non-comparator randomised phase II multi-center maintenance study of olaparib alone or olaparib in combination with durvalumab in platinum treated advanced triple negative breast cancer (TNBC).
SABCS.
미국
(2017)
Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single center breast cancer cohort.
SABCS.
미국
(2017)
Current landscape and future perspectives of biomarker study in breast cancer.
JSMO.
일본
(2017)
Recent Advances of Endocrine Therapy in Premenopausal Women with Breast Cancer.
APCC.
대한민국
(2017)
CIRCULATING TUMOR DNA PRESENTS VARIABLE CLONAL RESPONSE OF BREAST CANCER DURING NEOADJUVANT CHEMOTX.
GBCC.
대한민국
(2017)
INCIDENCE OF PERMANENT CHEMOTHERAPY-INDUCED ALOPECIA AMONG BREAST CANCER PATIENTS: A FIVE-YEAR PROSPECTIVE COHORT STUDY.
GBCC.
대한민국
(2016)
Year in review from Asia.
FACO-JSCO Joint Symposium.
일본
(2016)
Baseline molecular markers and risk of distant relapse in the NeoSphere study.
AACR.
미국
(2016)
Multi-omics and immuno-oncology profiling of an Asian breast cancer cohort enriched in young and premenopausal patients.
AACR.
미국
(2016)
EFFICACY AND SAFETY OF EVEROLIMUS AND EXEMESTANE IN PATIENTS WITH ADVANCED BREAST CANCER FROM ASIA AND AFRICA: ASIAN SUBSET RESULTS FROM THE PHASE 3B EVEREXES STUDY.
GBCC 2016.
대한민국
(2015)
Efficacy and safety of palbociclib plus fulvestrant in Asian women with hormone receptor-positive (HR+)/human epidermal growth factor-2 negative (HER2-) metastatic breast cancer (MBC) that progressed on prior endocrine therapy (ET).
ESMO ASIA.
싱가포르
(2015)
Clinical effectiveness of everolimus and exemestane in advanced breast cancer patients from Asia and Africa: First efficacy
and updated safety results from the phase IIIb EVEREXES study.
San Antonio Breast Cancer Symposium.
미국
(2015)
Prognostication of HER family gene expression collaborate with ESR1 expression in patients with triple negative breast cancer.
San Antonio Breast Cancer Symposium.
미국
(2015)
A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) versus physician's choice in BRCA mutation subjects with locally advanced and/or metastatic breast cancer..
San Antonio Breast Cancer Symposium.
미국
(2015)
Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen
receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors.
San Antonio Breast Cancer Symposium.
미국
